局灶进展性胃癌术前与术后行以多西紫杉醇为基础的辅助化疗比较

目的：比较局灶进展性胃癌（LAGC）术前与术后行以多西紫杉醇为基础的辅助化疗的疗效。 方法：将2011年2月—2012年2月间确诊为LAGC的患者72例随机均分为观察组和对照组。观察组行术前化疗，而对照组则行术后化疗。两组治疗后随访12个月，对比两组手术化疗周期、手术切除率、病理学缓解情况，以及两组不良反应和并发症情况和再次手术情况。 结果：两组共行化疗189个周期，其中观察组占比62.43%（118/189），对照组为37.57%（71/189）；观察组化疗1个周期者占4.24%（5/118），对照组为22.54%（16/71），差异均有统计学意义（均P<0.05）。观察组完全反应率为27.78%（10/36），部分反应率为63.89%（23/36），对照组为8.33%（3/36），38.89%（14/36），差异均有统计学意义（均P<0.05）。两组手术切除率及淋巴结清扫情况差异均无统计学意义（均P>0.05）。观察组中不良反应发生率低于对照组（P<0.05），但两组间术后并发症发生率及再次手术情况差异均无统计学意义（均P>0.05）。 结论：LAGC在术前行以多西紫杉醇为基础的辅助化疗可明显改善治疗效果，同时患者耐受性较好，不良反应少。

Preoperative versus postoperative docetaxel-based adjuvant chemotherapy for locally advanced gastric cancer

Objective: To compare the efficacy between preoperative and postoperative docetaxel-based adjuvant chemotherapy for locally advanced gastric cancer (LAGC). Methods: From February 2011 to February 2012, 72 patients definitely diagnosed with LAGC were randomized into observational group and control group. Patients in observational group underwent preoperative chemotherapy, while those in control group were subjected to postoperative chemotherapy. Patients in both groups were followed up for 12 months after treatment, and the cycles of chemotherapy, surgical resection rate and pathological remission rate, as well as the incidence of adverse reactions and complications between the two groups were compared. Results: In total, 189 cycles of chemotherapy were performed for the two groups, in which observational group accounted for 62.43% (118/189), and control group accounted for 37.57% (71/189); one cycle chemotherapy administration accounted for 4.24% (5/118) in observational group, which was 22.54% (16/71) in control group, and all differences were statistically significant (both P<0.05). The complete response rate was 27.78% (10/36) and partial response rate was 63.89% (23/36) in observational group, which was 8.33% (3/36) and 38.89% (14/36) respectively in control group, and the differences were statistically significant (both P<0.05). The difference in surgical resection rate and lymph node removal between the two groups showed no statistical significance (both P>0.05). The incidence of adverse reactions was significantly lower in observational group than that in control group (P<0.05), while the incidence of complications and re-operation between the two groups had no statistical significance (both P>0.05). Conclusion: Preoperative docetaxel-based adjuvant chemotherapy can significantly improve the therapeutic efficacy for LAGC patients, improve the tolerance of patients to chemotherapy, and reduce adverse reactions.